ID

25046

Descripción

Study ID: 101468/228 Clinical Study ID: 101468/228 Study Title:A two year Phase IIIb randomised, multicenter, double-blind, SINEMET controlled, parallel group, flexible dose study, to assess the effectiveness of controlled release ropinirole add-on therapy to L-dopa at increasing the time to onset of dyskinesia in Parkinson's disease subjects. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00363727 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication : Dyskinesias; Parkinson Disease; Parkinson's Disease Study part: L-Dopa medication

Palabras clave

Versiones (4)
  1. 18/8/17 18/8/17 -
  2. 18/8/17 18/8/17 -
  3. 25/8/17 25/8/17 -
  4. 8/9/17 8/9/17 -
Titular de derechos de autor

GlaxoSmithKline

Subido en

25 de agosto de 2017

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY-NC 3.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

L-Dopa medication GSK study Dyskinesia in Parkinson's disease NCT00363727

Inglés

L-Dopa medication GSK study Dyskinesia in Parkinson's disease NCT00363727

1 formularios  
General information
Descripción

General information

Protocol identifier
Descripción

Protocol identifier

Tipo de datos

text

Subject Identifier
Descripción

Subject Identifier

Tipo de datos

text

Alias
UMLS CUI [1]
C2348585
Visit Description
Descripción

Visit Description

Tipo de datos

text

L-Dopa medication changes
Descripción

L-Dopa medication changes

Has there been any change in dose or frequency of L-Dopa medication since the last visit?
Descripción

Note: Record any changes to the subject's L-Dopa medication taken since the last visit in the L-Dopa Medication section and contact GSK

Tipo de datos

boolean

L-Dopa medication
Descripción

L-Dopa medication

Drug name
Descripción

(Trade Name preferred)

Tipo de datos

text

Unit Dose
Descripción

Unit Dose

Tipo de datos

float

Units
Descripción

The following lists of abbreviations are examples which can be used to aid the completion of the appropriate items on the L-Dopa page.These are not all inclusive lists and are for guidance only, other abbreviations may be used if necessary. Abbreviation Label: TAB = Tablet, MCL = Microlitre, ML = Millilitre, L = Litre, MCG = Microgram, MG = Milligram, G = Gram

Tipo de datos

text

Frequency
Descripción

The following lists of abbreviations are examples which can be used to aid the completion of the appropriate items on the L-Dopa page.These are not all inclusive lists and are for guidance only, other abbreviations may be used if necessary. Abbreviation Label: OD = 1 x Daily, BID = 2 x Daily, TIO = 3x Daily, QID = 4x Daily, PRN = As required

Tipo de datos

text

Route
Descripción

The following lists of abbreviations are examples which can be used to aid the completion of the appropriate items on the L-Dopa page.These are not all inclusive lists and are for guidance only, other abbreviations may be used if necessary. Abbreviation Label: IM = Intramuscular, IH = Inhalation, IV = Intravenous, NS = Nasal, TP = Topical, PO = Oral, VG = Vaginal

Tipo de datos

text

Reason for Medication
Descripción

Reason for Medication

Tipo de datos

text

Start Date
Descripción

Start Date

Tipo de datos

date

Stop Date
Descripción

Stop Date

Tipo de datos

date

Ongoing Medication?
Descripción

Ongoing Medication

Tipo de datos

boolean

Parkinson's disease symptom control
Descripción

Parkinson's disease symptom control

Does the subject experience a reduction in Parkinson's Disease symptom control within 4 hours of the dose of L-dopa?
Descripción

Parkinson's Disease symptom control

Tipo de datos

boolean

Volver a la parte superior de la página

Similar models

L-Dopa medication GSK study Dyskinesia in Parkinson's disease NCT00363727

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
General information
Protocol identifier
Item
Protocol identifier
text
Subject Identifier
Item
Subject Identifier
text
C2348585 (UMLS CUI [1])
Visit Description
Item
Visit Description
text
Item Group
L-Dopa medication changes
change of L-Dopa medication
Item
Has there been any change in dose or frequency of L-Dopa medication since the last visit?
boolean
Item Group
L-Dopa medication
Drug name
Item
Drug name
text
Unit Dose
Item
Unit Dose
float
Units
Item
Units
text
Frequency
Item
Frequency
text
Route
Item
Route
text
Reason for Medication
Item
Reason for Medication
text
Start Date
Item
Start Date
date
Stop Date
Item
Stop Date
date
Ongoing Medication
Item
Ongoing Medication?
boolean
Item Group
Parkinson's disease symptom control
Parkinson's Disease symptom control
Item
Does the subject experience a reduction in Parkinson's Disease symptom control within 4 hours of the dose of L-dopa?
boolean
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial